Insilico, which uses AI to accelerate drug discovery, says early data shows that rentosertib, a drug developed to treat a chronic lung disease, could slow aging (Cade Metz/New York Times)

Insilico reports that early experimental data indicate rentosertib, originally developed for a chronic lung disease, may have the capability to slow the aging process. The company attributes this potential anti-aging effect to the drug’s AI-guided mechanism of action.